Evaxion biotech appoints dr. birgitte rØnØ as chief scientific officer

Copenhagen, denmark, sept. 21, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its senior director, immuno-oncology, birgitte rØnØ, ph.d, to the newly-created position of chief scientific officer, effective immediately.
EVAX Ratings Summary
EVAX Quant Ranking